Videos
HER2+ BC: Residual Disease After Neoadjuvant Therapy
Bassel El-Rayes, MD, discusses the key points physicians should consider when treating a patient with metastatic colorectal cancer.
Early HER2+ Breast Cancer
Multiple Myeloma
Noopur Raje, MD, discusses the current treatment options for patients diagnosed with multiple myeloma. At this time, a number of FDA-approved drugs and different combinations are available.
Case Based Peer Perspectives: Metastatic Castration-Resistant Prostate Cancer
Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Allostatic Load Emerges as a Risk Marker for Early-Onset Cancer
3
FDA Approves Expanded Automated PD-L1 Diagnostic Testing Across 4 Solid Tumor Types
4
Velzatinib Aims For Future Direct Comparison With Imatinib in GIST
5